Angiotensin IV raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-14. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
== Production == The Booth's beers are produced at four locations (The Booth's Pangyo Brewery, The Booth's Eureka Brewery, Brew Hub, and De Proefbrouwerij), on three continents (Asia, North America, and Europe). Production at Brew Hub has helped quintuple The Booth's production of their flagship beers, Kukmin IPA and Kieuk IPA. Its beers include Taedonggang Pale Ale: International Pale Ale, made in collaboration with Danish gypsy-brewery Mikkeller, and Kieuk Session IPA: Session India Pale Ale, made in collaboration with Kiha and the Faces, an indie music band from Korea. In October 2015, they acquired a brewing facility in Eureka, California, formerly owned by Lost Coast Brewery. In December 2020, the Eureka facility was shut down.
== 3D holograms == In 1976, he became the holography assistant for the American new media artist Al Razutis. In 1978 he received Canadian government funding to build his own holography studio and study holographic special effects. He exhibited the results of this work in Vancouver at the Helen Pitt Gallery in June 1978 and again in Victoria at the Open Space Gallery in June 1979.
== Intersectionality == Intersectionality is intersecting social identities and related systems of oppression, domination, or discrimination. In South Africa, Black lesbians may face homophobia, sexism, racism, and classism. Research in 2008 by Triangle Project, an LGBTQI rights group, revealed that Black lesbians were twice as afraid of sexual assault than white lesbians. Taking into account race and sexuality together is essential when examining corrective rape, as both subjects cross into each other and influence each other heavily. Intersectionality plays a major role in corrective rape cases. Sexuality and gender especially, define the social and political rank of victims. Many are ostracized, and other abusive measures are taken in order to "cure" individuals of their sexuality. According to Sarah Doan-Minh, corrective rape is a type of "systemic, group-based violence", which is deeply tied to traditional gender and sexual norms, rather than simply being the result of interpersonal dynamics.
positional cloning Also map-based cloning. A strategy for identifying and cloning a candidate gene based on knowledge of its locus or position alone and with little or no information about its products or function, in contrast to functional cloning. This method usually begins by comparing the genomes of individuals expressing a phenotype of unknown provenance (often a hereditary disease) and identifying genetic markers shared between them. Regions defined by markers flanking one or more genes of interest are cloned, and the genes located between the markers can then be identified by any of a variety of means, e.g. by sequencing the region and looking for open reading frames, by comparing the sequence and expression patterns of the region in mutant and wild-type individuals, or by testing the ability of the putative gene to rescue a mutant phenotype.
Sources: en.wikipedia.org
Australia has 43 universities, with 37 being public universities. The Group of Eight includes some of the oldest public universities in Australia, including the University of Queensland, University of Sydney, University of Melbourne, University of New South Wales, University of Adelaide, University of Western Australia, Australian National University, and Monash University. The Australian Technology Network of public universities grew from the former Institutes of Technology and include RMIT University, Queensland University of Technology, Curtin University, the University of Technology Sydney, and the University of South Australia. These former technology institutes gained university status in the late 1980s through the early 1990s due to the reforms made by John Dawkins, then Minister for Employment, Education, and Training. Innovative Research Universities represents several public research-intensive institutions, with most members being established in the 1960s and 1970s. The group includes Charles Darwin University, James Cook University, Griffith University, La Trobe University, Flinders University, Murdoch University, and Western Sydney University. The Regional Universities Network includes seven regional Australian public universities, including Central Queensland University, Southern Cross University, Federation University, the University of Southern Queensland, the University of the Sunshine Coast, University of New England (Australia), and Charles Sturt University.
== Treatment == Most (>95%) infants with biliary atresia will undergo an operation designed to retain and salvage the native liver, restore bile flow, and reduce the level of jaundice. This is known as the Kasai procedure (after Morio Kasai, the Japanese surgeon who first developed the technique) or hepatoportoenterostomy. Although the procedure is not thought of as curative, it may relieve jaundice and stop liver fibrosis, allowing normal growth and development. Published series from Japan, North America, and the UK show that bilirubin levels will fall to normal values in about 50-55% of infants, allowing 40-50% to retain their own liver to reach the age of 5 and 10 years (and beyond). Liver transplantation is an option for those children whose liver function and symptoms fail to respond to a Kasai operation. Recent large-scale studies by Davenport et al. (Annals of Surgery, 2008) show that the age of the patient is not an absolute clinical factor affecting prognosis. The influence of age differs according to the disease etiology—i.e., whether biliary atresia is isolated, cystic (CBA), or accompanied by splenic malformation (BASM). It is widely accepted that corticosteroid treatment after a Kasai operation, with or without choleretics and antibiotics, has a beneficial effect on postoperative bile flow and can clear jaundice, but there is currently no consensus on the ideal dosing and duration of steroid use.
=== Trypsin-like === Trypsin-like proteases cleave peptide bonds following a positively charged amino acid (lysine or arginine). This specificity is driven by the residue which lies at the base of the enzyme's S1 pocket (generally a negatively charged aspartic acid or glutamic acid).
Sources: en.wikipedia.org
== Aspergillus flavus == Aspergillus flavus is a fungus of the family Trichocomaceae with a worldwide distribution. The mold lives in soil, surviving off dead plant and animal matter, but spreads through the air via airborne conidia. This fungus grows in long branched hyphae and is capable of surviving on numerous food sources including corn and peanuts. Aspergillus species commonly cause disease in humans and other animals either through mycotoxicosis (poisoning) or through fungal infections. Aflatoxin B1 is a key contributor to the toxicity of foods contaminated with the fungus. A. flavus is capable of parasitizing many host species. In humans, Aspergillus flavus along with Aspergillus fumigatus are common agents of fungal infections referred to as aspergillosis. These species primarily infect the lungs of immune-compromised patients, but A. flavus infections of the skin, eye, and other organs also occur. Unlike many mold species, Aspergillus flavus prefers hot and dry conditions; its optimal growth at 37 °C (99 °F) contributes to its pathogenicity in humans. Species that do not grow well at body temperature cannot typically infect humans.
=== Aplastic anemia === In the early 1960s, potassium perchlorate used to treat Graves' disease was implicated in the development of aplastic anemia—a condition where the bone marrow fails to produce new blood cells in sufficient quantity—in thirteen patients, seven of whom died. Subsequent investigations have indicated the connection between administration of potassium perchlorate and development of aplastic anemia to be "equivocable at best", which means that the benefit of treatment, if it is the only known treatment, outweighs the risk, and it appeared a contaminant poisoned the 13.
On 28 September 2025, Noboa led a humanitarian convoy with UN and EU diplomats Laura Melo, Yekaterina Doródnova and Giovanni Davoli. The convoy, which was escorted by armed military, came under attack as protestors used Molotov cocktails and rocks in Cotacachi, Imbabura Province. The attack took place during nationwide strikes and protests about fuel subsidy cuts after an unarmed protestor, Efrain Fuerez, was shot dead by a soldier. It resulted in the kidnapping of 17 soldiers who were released four days later. The protests were led by the indigenous rights group Confederation of Indigenous Nationalities of Ecuador (CONAIE), who have reported repression by freezing the bank accounts of indigenous leaders and activists as well as the censorship of indigenous-led radio and TV channels. In response, Noboa declared a state of emergency in eight provinces, enforcing a curfew. On 23 October 2025, Noboa said he was the target of an assassination attempt using poisoned chocolate and jam. On 16 November 2025 a majority of Ecuadorians voted against allowing the return of foreign military bases in the country and drafting a new constitution, alongside other proposals in a referendum proposed by Noboa, being described as his first major political setback during his second term.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.